Carrie A Thompson1, Herve Ghesquieres2, Matthew J Maurer2, James R Cerhan2, Pierre Biron2, Stephen M Ansell2, Catherine Chassagne-Clément2, David J Inwards2, Thérèse Gargi2, Patrick B Johnston2, Emmanuelle Nicolas-Virelizier2, William R Macon2, Marie Peix2, Ivana N Micallef2, Catherine Sebban2, Grzegorz S Nowakowski2, Luis F Porrata2, George J Weiner2, Thomas E Witzig2, Thomas M Habermann2, Brian K Link2. 1. Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA. Thompson.Carrie@mayo.edu. 2. Carrie A. Thompson, Matthew J. Maurer, James R. Cerhan, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, William R. Macon, Ivana N. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Thomas E. Witzig, Thomas M. Habermann, Mayo Clinic, Rochester, MN; Herve Ghesquieres, Pierre Biron, Catherine Chassagne-Clément, Thérèse Gargi, Emmanuelle Nicolas-Virelizier, Marie Peix, Catherine Sebban, Centre Leon Berard, University of Lyon, Lyon, France; George J. Weiner and Brian K. Link, University of Iowa, Iowa City, IA.
Abstract
PURPOSE: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France. METHODS: Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records. RESULTS: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P = .56) and Lyon cohorts (P = .25). CONCLUSION: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.
PURPOSE: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France. METHODS:Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records. RESULTS: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P = .56) and Lyon cohorts (P = .25). CONCLUSION: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.
Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: K Nakamura; M Sasaki; N Kunitake; M Kimura; T Watanabe; T Sasaki; H Terashima; Y Kuwabara; S Sakai; K Masuda Journal: Int J Clin Oncol Date: 2001-12 Impact factor: 3.402
Authors: Paul A Hamlin; Andrew D Zelenetz; Tarun Kewalramani; Jing Qin; Jaya M Satagopan; David Verbel; Ariela Noy; Carol S Portlock; David J Straus; Joachim Yahalom; Stephen D Nimer; Craig H Moskowitz Journal: Blood Date: 2003-04-03 Impact factor: 22.113
Authors: T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau Journal: N Engl J Med Date: 1995-12-07 Impact factor: 91.245
Authors: Rachel E Lerner; William Thomas; Todd E Defor; Daniel J Weisdorf; Linda J Burns Journal: Biol Blood Marrow Transplant Date: 2007-02-15 Impact factor: 5.742
Authors: Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger Journal: Blood Date: 2007-03-27 Impact factor: 22.113
Authors: Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht Journal: Blood Date: 2017-08-03 Impact factor: 22.113
Authors: Sweet Ping Ng; Courtney Pollard; Joel Berends; Zeina Ayoub; Mona Kamal; Adam S Garden; Houda Bahig; Scott B Cantor; Andrew J Schaefer; Temitayo Ajayi; G Brandon Gunn; Steven J Frank; Heath Skinner; Jack Phan; William H Morrison; Renata Ferrarotto; Jason M Johnson; Abdallah S R Mohamed; Stephen Y Lai; Amy C Hessel; Erich M Sturgis; Randal S Weber; Clifton D Fuller; David I Rosenthal Journal: Cancer Date: 2019-02-12 Impact factor: 6.860
Authors: Mark Roschewski; Kieron Dunleavy; Stefania Pittaluga; Martin Moorhead; Francois Pepin; Katherine Kong; Margaret Shovlin; Elaine S Jaffe; Louis M Staudt; Catherine Lai; Seth M Steinberg; Clara C Chen; Jianbiao Zheng; Thomas D Willis; Malek Faham; Wyndham H Wilson Journal: Lancet Oncol Date: 2015-04-01 Impact factor: 41.316
Authors: Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann Journal: Lancet Haematol Date: 2018-06-18 Impact factor: 18.959